-
The flow-directed stent was approved for marketing
Time of Update: 2022-10-31
Recently, after review, the State Medical Products Administration approved the registration of the innovative product "blood flow directed dense mesh stent" produced by Eco Medical Device (Beijing) Co.
-
Hand in hand, empowering innovation, Thermo Flying to the "Appointment of the Expo"
Time of Update: 2022-10-25
Shanghai, October 20, 2022 – The closely watched 5th China International Import Expo (CIIE) is about to officially kick off. Thermo Fisher Scientific (hereinafter referred to as Thermo Fisher Fisher
-
BGI Group obtains the first clinical laboratory certification in Australia
Time of Update: 2022-10-25
" ” BGI Group has been committed to building an international high-quality laboratory, providing accurate and reliable test results for partners, establishing a comprehensive quality management system, covering scientific research cooperation, clinical services, instrument manufacturing, reagent production, data analysis, etc.
-
The government subsidizes the support of university scientific research and medical research equipment renovation project - Gene Co., Ltd. Solution
Time of Update: 2022-10-25
Policy interpretation Premier Li Keqiang presided over an executive meeting of the State Council on September 7, including the People's Bank of China's establishment of a special reloan for equipment
-
HKU-Shenzhen Hospital completed the first clinical service case of brain "magnetic wave knife" in China
Time of Update: 2022-10-25
The University of Hong Kong-Shenzhen Hospital (hereinafter referred to as "HKU-Shenzhen Hospital") announced on the 18th that Mr. Wang, who has suffered from essential tremor for many years, recently successfully performed magnetic resonance guided focused ultrasound (MRgFUS, also known as "magnetic wave knife") treatment in the hospital, which solved the problem of tremor in the right hand.
-
The State Food and Drug Administration approved the marketing of cold and wet granules
Time of Update: 2022-10-25
js?cdnversion='+~(-new Date()/36e5)]; Recently, the State Medical Products Administration approved the marketing of Class 3.
js?cdnversion='+~(-new Date()/36e5)]; Recently, the State Medical Products Administration approved the marketing of Class 3.
js?cdnversion='+~(-new Date()/36e5)]; Recently, the State Medical Products Administration approved the marketing of Class 3.
-
The drug stability test chamber industry is developing rapidly, and the bottleneck of technical "stuck neck" has yet to be broken
Time of Update: 2022-10-25
At present, the domestic pharmaceutical industry is accelerating innovation and development, and the future market prospects of drug stability test chambers are considerable, but domestic enterprises still need to keep pace with the times, maintain innovation, continuously increase investment in research and development, and create equipment that meets the requirements of domestic pharmaceutical companies and has hard core and independent property rights, in order to occupy more market cakes in the market.
-
Chinese experts have discovered a new direction for precision treatment of triple-negative breast cancer
Time of Update: 2022-10-25
(End) Due to high heterogeneity, poor prognosis, and high risk of recurrence and metastasis, triple-negative breast cancer has become a stubborn "fortress" that needs to be overcome urgently in breast cancer research.
-
【Net Derui Live】Pharmaceutical water system design standard specifications
Time of Update: 2022-10-25
js?cdnversion='+~(-new Date()/36e5)]; At 14:00 pm on October 20th, Jingderui will bring you the theme of "Pharmaceutical Water System Design Standard Specification" live broadcast, sharing and communicating with you the design standards and process selection design of pharmaceutical water, welcome to watch on time!
-
【10.21 Live】Calibration of radiation thermometer for work
Time of Update: 2022-10-25
Fluke temperature application experts will introduce in detail the calibration knowledge of radiation thermometers from the interpretation of verification regulations, the determination of verification parameters, and the selection of radiation sources, as well as how to choose the appropriate calibration scheme for different temperature measurement applications.
-
World Anesthesia Day 2022: Baxter is committed to advancing anesthesiology and protecting life from love
Time of Update: 2022-10-20
prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.
prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.
prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.
prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.
prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.
prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.
-
Yunzhou Biotech received a Series C investment of 410 million yuan to accelerate the global life science and gene drug research and development process
Time of Update: 2022-10-20
/* Style Definitions */ span. prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a. prnews_a { color:blue; } li. prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p. prnews
-
WuXi Biologics Wins CDMO of the Year
Time of Update: 2022-10-20
HK), a leading global contract research, development and manufacturing (CRDMO) services company, announced its 2022 Asia-Pacific Biologics CMO Excellence at IMAPAC Awards, APBCEA) won the "CDMO of the Year" award.
-
Ascend launches HiDura? MED product portfolio
Time of Update: 2022-10-20
HiDura MED polyamide produced by Ascend Performance Materials is used in medical durables, drug delivery, surgical instruments, medical devices and wound care.
HiDura MED polyamide produced by Ascend Performance Materials is used in medical durables, drug delivery, surgical instruments, medical devices and wound care.
-
Intracranial aneurysm surgery planning software was approved for marketing
Time of Update: 2022-10-20
The products are used for the display, segmentation, measurement and processing of X-ray angiography three-dimensional body images in patients with cerebrovascular diseases, and to assist doctors in performing microcatheter path and shaping planning for aneurysm coil embolization during neurointerventional surgery.
-
WuXi Biologics and Japan's Toregem BioPharma signed a memorandum of understanding on the development of anti-USAG-1 antibodies
Time of Update: 2022-10-20
" " Dr. Zhisheng Chen, CEO of WuXi Biologics, said, "We are excited to be a partner of Toregem to accelerate the TRG035 development process through end-to-end services and professional insights, which is the first comprehensive project empowered by WuXi Biologics in the Japanese market from early-stage scientific research to clinical stage.
-
The future of DNA and data storage
Time of Update: 2022-10-20
Scan the code to read the full white paper Tremendous technological advances have brought us into a digital age that generates data at an exponential rate.
Scan the code to read the full white paper Tremendous technological advances have brought us into a digital age that generates data at an exponential rate.
-
Australian study: The impact of long-term new crown symptoms cannot be ignored
Time of Update: 2022-10-20
hospitals According to data from the Australian Federal Ministry of Health, Australia, with a total population of more than 25 million, has a cumulative total of more than 10 million confirmed cases of new crowns.
-
The Oxford-AstraZeneca nasal vaccine has performed poorly in clinical trials
Time of Update: 2022-10-20
” Since the early days of the pandemic, researchers have been working to develop a SARS-CoV-2 vaccine that can be injected in the form of a nasal spray because the spray is simpler than injection and could theoretically boost immune protection when coronavirus enters the body.
-
BRUKINSA? (zebrutinib) vs. Eco? A Phase 3 clinical trial (ibrutinib) for chronic lymphocytic leukemia yielded positive results in an end-of-life analysis of progression-free survival
Time of Update: 2022-10-20
62em; font-family:"Arial"; color:black; margin:0in; } BEIJING, China, Cambridge, Massachusetts and Basel, Switzerland, Oct. 12, 2022 /PRNewswire/ -- BeiGene (NASDAQ: BGNE; HKEx code: 06160; SSE: 688235) is a global biotechnology company focused on developing innovative, affordable anti-tumor drugs for patients around the world, improving patient outcomes and increasing drug access.
